Cargando…

Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies

Periodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host'...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavanelli, Angelica Leticia Reis, de Menezes, Bruna Silva, Pereira, Erica Bianca Barbosa, de Souza Morais, Fabio Assuncao, Cirelli, Joni Augusto, de Molon, Rafael Scaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085331/
https://www.ncbi.nlm.nih.gov/pubmed/35547360
http://dx.doi.org/10.1155/2022/5832009
_version_ 1784703791339143168
author Pavanelli, Angelica Leticia Reis
de Menezes, Bruna Silva
Pereira, Erica Bianca Barbosa
de Souza Morais, Fabio Assuncao
Cirelli, Joni Augusto
de Molon, Rafael Scaf
author_facet Pavanelli, Angelica Leticia Reis
de Menezes, Bruna Silva
Pereira, Erica Bianca Barbosa
de Souza Morais, Fabio Assuncao
Cirelli, Joni Augusto
de Molon, Rafael Scaf
author_sort Pavanelli, Angelica Leticia Reis
collection PubMed
description Periodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host's immune response, which is characterized by increased expression of several inflammatory mediators such as cytokines and chemokines in the connective tissue. If periodontal disease (PD) is left untreated, it results in the destruction of the supporting tissues around the teeth, including periodontal ligament, cementum, and alveolar bone, which lead to a wide range of disabilities and poor quality of life, thus imposing significant burdens. This process depends on the differentiation and activity of osteoclasts, the cells responsible for reabsorbing the bone tissue. Therefore, the inhibition of differentiation or activity of these cells is a promising strategy for controlling bone resorption. Several pharmacological drugs that target osteoclasts and inflammatory cells with immunomodulatory and anti-inflammatory effects, such as bisphosphonates, anti-RANK-L antibody, strontium ranelate, cathepsin inhibitors, curcumin, flavonoids, specialized proresolving mediators, and probiotics, were already described to manage inflammatory bone resorption during experimental PD progression in preclinical studies. Meantime, a growing number of studies have described the beneficial effects of herbal products in inhibiting bone resorption in experimental PD. Therefore, this review summarizes the role of several pharmacological drugs used for PD prevention and treatment and highlights the targeted action of all those drugs with antiresorptive properties. In addition, our review provides a timely and critical appraisal for the scientific rationale use of the antiresorptive and immunomodulatory medications in preclinical studies, which will help to understand the basis for its clinical application.
format Online
Article
Text
id pubmed-9085331
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90853312022-05-10 Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies Pavanelli, Angelica Leticia Reis de Menezes, Bruna Silva Pereira, Erica Bianca Barbosa de Souza Morais, Fabio Assuncao Cirelli, Joni Augusto de Molon, Rafael Scaf Biomed Res Int Review Article Periodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host's immune response, which is characterized by increased expression of several inflammatory mediators such as cytokines and chemokines in the connective tissue. If periodontal disease (PD) is left untreated, it results in the destruction of the supporting tissues around the teeth, including periodontal ligament, cementum, and alveolar bone, which lead to a wide range of disabilities and poor quality of life, thus imposing significant burdens. This process depends on the differentiation and activity of osteoclasts, the cells responsible for reabsorbing the bone tissue. Therefore, the inhibition of differentiation or activity of these cells is a promising strategy for controlling bone resorption. Several pharmacological drugs that target osteoclasts and inflammatory cells with immunomodulatory and anti-inflammatory effects, such as bisphosphonates, anti-RANK-L antibody, strontium ranelate, cathepsin inhibitors, curcumin, flavonoids, specialized proresolving mediators, and probiotics, were already described to manage inflammatory bone resorption during experimental PD progression in preclinical studies. Meantime, a growing number of studies have described the beneficial effects of herbal products in inhibiting bone resorption in experimental PD. Therefore, this review summarizes the role of several pharmacological drugs used for PD prevention and treatment and highlights the targeted action of all those drugs with antiresorptive properties. In addition, our review provides a timely and critical appraisal for the scientific rationale use of the antiresorptive and immunomodulatory medications in preclinical studies, which will help to understand the basis for its clinical application. Hindawi 2022-05-02 /pmc/articles/PMC9085331/ /pubmed/35547360 http://dx.doi.org/10.1155/2022/5832009 Text en Copyright © 2022 Angelica Leticia Reis Pavanelli et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Pavanelli, Angelica Leticia Reis
de Menezes, Bruna Silva
Pereira, Erica Bianca Barbosa
de Souza Morais, Fabio Assuncao
Cirelli, Joni Augusto
de Molon, Rafael Scaf
Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies
title Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies
title_full Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies
title_fullStr Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies
title_full_unstemmed Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies
title_short Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies
title_sort pharmacological therapies for the management of inflammatory bone resorption in periodontal disease: a review of preclinical studies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085331/
https://www.ncbi.nlm.nih.gov/pubmed/35547360
http://dx.doi.org/10.1155/2022/5832009
work_keys_str_mv AT pavanelliangelicaleticiareis pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies
AT demenezesbrunasilva pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies
AT pereiraericabiancabarbosa pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies
AT desouzamoraisfabioassuncao pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies
AT cirellijoniaugusto pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies
AT demolonrafaelscaf pharmacologicaltherapiesforthemanagementofinflammatoryboneresorptioninperiodontaldiseaseareviewofpreclinicalstudies